Tumor tissue collected at diagnosis was available only for one (ID#88) out of 3 KRAS positive patients, and its analysis confirmed the co-existence of EGFR and KRAS mutations (KRAS allelic frequency 13.8%). This evidence concerns the gene EGFR and neoplasm.